12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

WT1 DNA vaccine: Phase II started

Inovio began an open-label, U.K. Phase II trial to evaluate 6 vaccinations of its WT1 DNA vaccine given every 4 weeks in up to 184 AML or CML patients. Responders may continue to receive...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >